Lipid Gene Therapy

Definition

Gene editing therapies (GET) targeting hepatically expressed lipid metabolism genes to achieve durable, potentially one-time reductions in atherogenic lipoproteins. Unlike RNA interference agents (inclisiran, siRNA) that require repeat dosing, GET delivers permanent genomic edits to hepatocytes via lipid nanoparticle (LNP) or GalNAc-conjugated delivery — exploiting the asialoglycoprotein receptor to ensure hepatic specificity.

Key Concepts

Scientific Rationale

• Lipid metabolism genes are ideal LNP-GET targets: (1) expressed exclusively or predominantly in hepatocytes; (2) loss-of-function variants in humans are naturally associated with lower CVD risk, providing genetic validation of the target (sources/gene-editing-acc-2026 — very high)
• Individuals with naturally occurring LOF variants in PCSK9 have lower LDL-C and fewer ASCVD events; those with LOF in ANGPTL3 have lower LDL-C + TG + lower CAD event rates; LPA variation is the primary determinant of Lp(a) levels (a causal risk factor)
• GalNAc conjugation ensures hepatic specificity via high-affinity binding to asialoglycoprotein receptors on hepatocytes — minimizes off-target effects in other organs (sources/gene-editing-acc-2026 — very high)

PCSK9 Gene Editing (Clinical)

• VERVE-102 / Heart-2 (Verve Therapeutics/Eli Lilly; Phase 1; NCT06164730) — NEJM 2026: GalNAc-LNP encapsulating mRNA-encoded adenine base editor (ABE8.8) + gRNA targeting PCSK9 splice site (5' intron 1); A→G base substitution disrupts splicing → read-through to stop codon → permanent hepatic PCSK9 inactivation; single IV infusion; n=35 (HeFH or premature CAD on max oral LLD); 6 dose cohorts 0.3–1.0 mg/kg; data cutoff Feb 27, 2026 (non-prespecified interim analysis) (sources/verve102-pcsk9-nejm-2026 — high; sources/gene-editing-acc-2026 — very high)
  • Safety: No dose-limiting toxicity, no deaths; 20% mild-moderate infusion-related reactions; transient ALT ≤2.4×ULN in 3/35 (peak day 3–4, resolved by day 8); no thrombocytopenia (improvement over predecessor VERVE-101); 1 grade 3 aspiration pneumonitis assessed as unrelated to drug; LNP t½ <20 hours
  • PCSK9 reduction (time-averaged from day 28): −51% at 0.3 mg/kg → −88% at 1.0 mg/kg (range −94 to −78%); 88% suppression consistent with near-complete elimination of hepatic PCSK9 production
  • LDL-C reduction: −9% at 0.3 mg/kg → −62% at 1.0 mg/kg (range −79 to −45%); absolute reduction −78 mg/dL (baseline 128 → achieved 51 mg/dL) at highest dose; comparable to long-term PCSK9 inhibitor therapy (40–60% on ongoing dosing) from a single infusion
  • Durability: Stable PCSK9 and LDL-C reductions to ≥18 months in participants with longest follow-up (n=15 with ≥1 year); day-28 values consistent with time-averaged values → edit persists through hepatocyte turnover (hepatocyte lifespan 200–300 days)
  • Projected ASCVD benefit: 78 mg/dL sustained LDL-C reduction over 20 years predicted to reduce ASCVD risk >50% in most hypercholesterolaemia patients
• YOLT-101 (Yoltech Therapeutics; Phase 1; NCT06461702): LNP-based PCSK9 gene silencing; showed >50% LDL-C reduction in small cohort with hypercholesterolemia (sources/gene-editing-acc-2026 — very high)
• ART002 (Accuredit Therapeutics; Phase 1): LNP-based PCSK9 gene editing; >50% LDL-C reduction in separate small cohort (sources/gene-editing-acc-2026 — very high)

ANGPTL3 Gene Editing (Clinical)

• BE3-Angptl3 (Chadwick et al.; murine proof-of-concept): 3rd-generation base editor + gRNA targeting murine Angptl3 Gln135; median 35% editing rate; no detectable off-target mutagenesis at 10 top predicted sites; −49% ANGPTL3, −31% TG, −19% LDL-C vs non-targeting gRNA control — validated durable base editing for ANGPTL3 in animal models (sources/angptl3-inhibition-tcm-2024 — high)
• CTX310 (CRISPR Therapeutics; Phase 1): LNP-encapsulated CRISPR-Cas9 editor targeting ANGPTL3; 15 patients with severe hyperlipidemias; few adverse events; at highest dose: mean LDL-C −49%, TG −55%; reductions in ANGPTL3 protein levels confirmed (sources/gene-editing-acc-2026 — very high)
• VERVE-201 / Pulse-1 (Verve Therapeutics; Phase 1b; NCT06451770): mRNA-encoded adenine base editor + gRNA via GalNAc-LNP targeting ANGPTL3; for patients with homozygous FH and refractory hypercholesterolaemia (ANGPTL3 acts independent of LDL receptor — key advantage for HoFH where LDLR is defective) (sources/gene-editing-acc-2026 — very high)
• Mechanistic note: ANGPTL3 blocks lipolysis of TG-rich lipoproteins via LPL inhibition AND raises LDL-C through endothelial lipase inhibition of VLDL clearance; ANGPTL3 LOF lowers LDL-C through a mechanism independent of the LDL receptor — enabling treatment of HoFH (where PCSK9 editing is less effective due to absent/non-functional LDLR) (sources/angptl3-inhibition-tcm-2024 — high)

LPA / Apolipoprotein(a) Gene Editing (Preclinical → Early Clinical)

• CTX320 (CRISPR Therapeutics): Dose-dependent LPA editing in primary human hepatocytes in vitro; Lp(a) −94% in non-human primates in vivo at 7 months; Phase 1 in development (sources/gene-editing-acc-2026 — very high)
• VERVE-301 (Verve Therapeutics): Advanced to clinical development targeting LPA (sources/gene-editing-acc-2026 — very high)
• CRISPR Therapeutics also initiating Phase 1 for Lp(a) elevation + established CVD
• LPA encodes apolipoprotein(a), the unique protein component of Lp(a); variation in LPA copy number is the primary determinant of plasma Lp(a) — a strongly atherogenic and thrombogenic lipoprotein not reduced by statins or PCSK9 inhibitors

APOC3 Gene Editing (Early Clinical)

• CorrectSequence Therapeutics: Base editing trial for APOC3-directed GET in familial chylomicronemia syndrome (a monogenic severe hypertriglyceridemia due to LOF in lipoprotein lipase/related genes where APOC3 inhibition reduces TG-rich lipoprotein levels) (sources/gene-editing-acc-2026 — very high)

Angiotensinogen (AGT) Gene Editing — Refractory Hypertension

• CTX340 (CRISPR Therapeutics): LNP-based GET targeting hepatically expressed AGT — master regulator of the renin-angiotensin-aldosterone system; advanced to clinical development for refractory hypertension (sources/gene-editing-acc-2026 — very high)
• First GET targeting the RAAS rather than a lipid target

Primary Prevention Implications

• PCSK9, ANGPTL3, and LPA GET represent potential primary prevention tools — somatic editing in high-risk but asymptomatic individuals before disease manifestation could provide lifelong protection from ASCVD with a single intervention
• Proof-of-concept in animal models + early human Phase 1 data support profound and sustained lipid lowering
• Extending to primary prevention requires more stringent safety evaluation and long-term registries (sources/gene-editing-acc-2026 — very high)

Contradictions / Open Questions

• No long-term safety data: All clinical GET trials for lipid targets are Phase 1 (PCSK9, ANGPTL3) or preclinical (LPA/APOC3); no CV outcomes trial exists; off-target editing causing malignancy may emerge over decades — FDA requires 15-year minimum follow-up for gene therapies; VERVE-102 Heart-2 participants will enroll in a 15-year long-term follow-up study (sources/gene-editing-acc-2026 — very high; sources/verve102-pcsk9-nejm-2026 — high)
• MAGNITUDE hepatotoxicity precedent: The MAGNITUDE Phase 3 pause (TTR target, also LNP-delivered CRISPR) for severe hepatotoxicity including one death raises the question of whether LNP-CRISPR hepatotoxicity is target-specific (TTR) or a class effect that could manifest with PCSK9/ANGPTL3/LPA editing at larger scale (sources/gene-editing-acc-2026 — very high)
• PCSK9 editing vs. inclisiran/evolocumab — durability vs. safety trade-off uncharacterised: Inclisiran (GalNAc-siRNA) achieves ~50% LDL-C reduction with twice-yearly SC dosing without permanent genomic change; PCSK9 inhibitors (evolocumab/alirocumab) have >5-year CV outcomes data. Whether the one-time convenience of permanent PCSK9 base editing justifies the unknown long-term genomic risks versus well-characterised existing agents remains unanswered (sources/gene-editing-acc-2026 — very high)
• HoFH and LDLR-dependent strategies: PCSK9 editing (which works by sparing LDL receptor from degradation) is less effective in HoFH patients with absent/severely dysfunctional LDLR; ANGPTL3 editing (LDLR-independent) is therefore the rationale for HoFH-focused trials — comparative efficacy not yet established (sources/gene-editing-acc-2026 — very high)
• Germline transmission risk: Somatic editing of hepatocytes should not affect germline, but rigorous exclusion is required; current trials preferentially enroll adults past reproductive age or use contraception protocols (sources/gene-editing-acc-2026 — very high)

Connections

• Related to concepts/CRISPR-Cas9-in-Channelopathies — editing platform
• Related to concepts/Gene-Editing-Risk-Benefit-Framework — patient selection; primary prevention expansion
• Related to concepts/AAV-Gene-Delivery — contrast: lipid targets use LNP not AAV
• Related to concepts/Gene-Silencing-Therapy — contrast: GET permanent vs. siRNA/ASO repeated dosing
• Related to concepts/Dyslipidemia-Management — pharmacological context
• Related to entities/Familial-Hypercholesterolemia — primary therapeutic target
• Related to entities/ATTR-Amyloidosis — parallel LNP-GET application; MAGNITUDE hepatotoxicity precedent

Sources

• sources/verve102-pcsk9-nejm-2026 — VERVE-102 Heart-2 Phase 1 NEJM 2026; full dose-response data; safety profile; durability to 18 months
• sources/gene-editing-acc-2026
• sources/angptl3-inhibition-tcm-2024 — BE3-Angptl3 murine proof-of-concept; ANGPTL3 biology and LDLR-independent mechanism